Navigation Links
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Date:8/2/2009

STAMFORD, Conn. and PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced entry into an exclusive license and collaboration agreement to commercialize Intermezzo((R)) (zolpidem tartrate sublingual tablet) in the United States. If approved by the U.S. Food and Drug Administration (FDA), Intermezzo((R)) has the potential to be the first prescription sleep aid specifically approved for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The FDA has established October 30, 2009 as the Prescription Drug User Fee Act (PDUFA) action date for the Intermezzo((R)) New Drug Application (NDA).

In the agreement announced today, Transcept has granted Purdue and a Purdue associated company an exclusive license to market, sell and distribute Intermezzo((R) )in the United States and the right to negotiate for the commercialization of the product in Canada and Mexico. Transcept has retained an option to co-promote Intermezzo((R) )to psychiatrists in the United States and has retained rights to commercialize Intermezzo((R)) in the rest of the world.

Under the terms of the agreement, Purdue will pay Transcept near-term milestones that include an upfront cash payment of $25 million and an additional payment of up to $30 million based upon the timing of an FDA approval of Intermezzo((R)), which approval and payment are subject to review and acceptance by Purdue. Transcept is eligible to receive up to an additional $90 million upon reaching future milestones related to achievement of intellectual property and U.S. net sales targets.

Purdue will pay double-digit royalties to Transce
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.; Purdue Pharmaceutical Products L.P.
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Purdue creating wireless sensors to monitor bearings in jet engines
2. Purdue leads center to simulate behavior of micro-electromechanical systems
3. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
4. Purdue researcher invents molecule that stops SARS
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 Vestiage, Inc. ... company focused on science-based research and development, sales ... cosmeceuticals and nutraceuticals, announced today that it is ... for the sale of Reluma Skin Illuminating Facial ... and application by sending an email to info(at)vestiageinc(dot)com ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season.   ... will work to support awareness of umbilical cord blood ...
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
Breaking Biology Technology:Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
... of enzymes routinely used to synthesizing some of nature's most ... new way to expand on nature's chemical creativity to make ... 1) in the journal Science , a team led ... the University of Wisconsin-Madison , describes the discovery of ...
... the new darling of Wall Street. In the past ... private equity firms, venture capital firms, and hedge funds. ... trading multiples in excess of $5 per gallon of ... EBITDA, and 1,000x trailing four quarters of net income. ...
... - When it comes to attracting venture capital, Wisconsin has ... Investors on the East and West coasts have basically stuck ... in the Heartland, with the exception of a few states ... have been signs that a few flights ferrying venture capitalists ...
Cached Biology Technology:UW finds new path to anti-cancer agents 2UW finds new path to anti-cancer agents 3Ethanol producers are at a crossroads 2Ethanol producers are at a crossroads 3Ethanol producers are at a crossroads 4Ethanol producers are at a crossroads 5Ethanol producers are at a crossroads 6That blip on the national venture capital radar screen may be Wisconsin 2That blip on the national venture capital radar screen may be Wisconsin 3
(Date:5/23/2013)... succeeded in treating cerebral palsy with autologous cord blood. ... 2.5 year old boy had been in a persistent ... two months after treatment with the cord blood containing ... months, the child learned to speak simple sentences and ... Korean study, dispel the long-held doubts about the effectiveness ...
(Date:5/23/2013)... world,s largest and fastest growing open-access publishers, announces ... in Bioengineering and Biotechnology . , A ... in Bioengineering and Biotechnology will provide a ... and biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web ...
(Date:5/23/2013)... In an age when microbial pathogens are growing increasingly ... infection, a team of Wisconsin scientists has synthesized a ... bacteria that cause staph infections. , Writing online in ... a group led by University of Wisconsin-Madison chemistry Professor ... "quorum sensing" behavior of Staphylococcus aureus , a ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2
... invasive alien freshwater mussel species the zebra mussel and ... by calcium levels in streams and lakes and a new ... and American Southwest could be next in line for invasion. ... the online version of Frontiers in Ecology and the Environment, ...
... Dec. 3 A team of researchers from the Wellman ... Medical School (HMS) have developed an optical device that allows ... monitor the cells passing through its bloodstream. In ... by the Optical Society of America, the team describes how ...
... extraordinary ability to remember numerals that is superior to ... 4th issue of Current Biology, a publication of Cell ... biologists, who believe that humans are superior to chimpanzees ... University. No one can imagine that chimpanzeesyoung chimpanzees at ...
Cached Biology News:New map outlines risk of zebra mussel invasion 2New map outlines risk of zebra mussel invasion 3New map outlines risk of zebra mussel invasion 4Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream 2Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream 3Young chimps top adult humans in numerical memory 2
... 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat inactivation ... Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM KCl, ... BSA, 50% glycerol. Shipping and Storage: Shipped on ... unit is defined as the amount of enzyme ...
... stainless-steel shaker flask clips, purpose-designed to firmly ... All clips are equipped with a top ... include a bottom retainer spring, and silicon ... expensive glassware. Clips include the required ...
ANTI DIPHTH TOX A SU...
... Assay Kit (E-22013) provides,researchers with a ... lysozyme,activity in solution. This fluorescence-based assay ... U/mL (Figure 1). The assay,measures lysozyme ... are labeled to such a degree ...
Biology Products: